Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers
February 2022
in “
Cancers
”
Studysummary This review discusses managing prostate cancer in patients with high-risk germline mutations and highlights the need for more research and consensus guidelines, reporting no new clinical results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document reviewed the clinical management of prostate cancer in men with high-risk germline genetic mutations, such as BRCA 1, BRCA 2, ATM, CHECK 2, and HOX B13, which increased the risk of aggressive cancer and metastases. It emphasized the importance of genetic testing and personalized treatment strategies, noting the lack of approved prevention agents and the need for more intensive screening protocols. Active surveillance was not recommended for high-risk mutation carriers, with radical treatment preferred. The document highlighted the potential of PARP inhibitors and cisplatin-based chemotherapy, especially for biochemical recurrence, and called for further research and consensus guidelines to improve management strategies for these individuals.
